Beijing: China has 11 candidates for Covid-19 vaccines under different stages of human trials, four of them are in the final tests and could be available in November, Prensa Latina publishes.
According to the Minister of Science and Technology, Wang Zhigang, of the most advanced three are of the inactivated type and the fourth is recombinant.
While Wu Guizhen, from the National Center for Disease Control and Prevention, assured that the investigations are flowing smoothly and the population could receive some of the preparations in November and December.
Preliminary results – he indicated – demonstrated the effectiveness of the drugs to produce antibodies in less than a month after applying the first dose and it is expected to guarantee protection between one and three years.
It also ensured the safety of Chinese vaccines in the event of a SARS-CoV-2 coronavirus mutation.
Regarding prices, the National Biotechnology Group commented that they would be around one thousand yuan (146.3 dollars), but they will be set together when the final tests are completed and the amount of doses necessary for immunization is determined.
It confirmed the inclusion of thousands of children over three years of age, adolescents and the elderly in clinical trials, with promising results.
But at the moment he did not recommend administering any of the drugs in pregnant women.
China vaccinated more than 100,000 foreign service, military, aviation and health workers since last July 22, when it approved the emergent use of its most advanced vaccines.
The country has been 33 consecutive days without autochthonous cases of Covid-19 and only reports imported among people arriving from abroad.
Hong Kong remains with the most complex scenario as a result of the regrowth that emerged in July and that shot 4,996 sick people and 103 the fatal number.
In general, China accumulates 4,744 deaths and 90,800 confirmed patients of the respiratory condition.